<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437539</url>
  </required_header>
  <id_info>
    <org_study_id>2014-730</org_study_id>
    <secondary_id>2014-005522-35</secondary_id>
    <nct_id>NCT02437539</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography</brief_title>
  <acronym>uPAR-PET</acronym>
  <official_title>68Ga-NOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor), for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Human</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Curasight</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to test a new radiotracer called 68Ga-NOTA-AE105 for
      PET imaging of uPAR (urokinase plasminogen activator receptor). The tracer has the potential
      of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and
      less aggressive tumors. This is a first in human study to test the radiotracer in cancer
      patients. The biodistribution and tumor uptake will be evaluated by repeated PET imaging (10
      minutes, 1 hour and 2 hours post injection).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to test a new radiotracer called 68Ga-NOTA-AE105 for
      PET imaging of uPAR (urokinase plasminogen activator receptor). The tracer has the potential
      of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and
      less aggressive tumors. This is a first in human study to test the radiotracer in cancer
      patients. The biodistribution and tumor uptake will be evaluated by repeated PET scans (10
      minutes, 1 and 2 hours post injection). The primary end points are safety, biodistribution
      and dosimetry of 68Ga-NOTA-AE105. In addition, the quantitative uptake of 68Ga-NOTA-AE105
      will be compared to the expression of uPAR measured directly in tumor tissue obtained by
      surgery or biopsies. The project will be monitored and evaluated in accordance with the
      principles of Good Clinical Practice (GCP).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution</measure>
    <time_frame>2 hours</time_frame>
    <description>The patients will be PET scanned 10 minutes, 1 hour and 2 hours post injection of the radiotracer 68Ga-NOTA-AE105. These timepoints will be used for assessment of biodistribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosimetry</measure>
    <time_frame>2 hours</time_frame>
    <description>The patients will be PET scanned 10 minutes, 1 hour and 2 hours post injection of the radiotracer 68Ga-NOTA-AE105. These timepoints will be used for calculation of dosimetry with the use of OLINDA/EXM software (mSv)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>2 hours</time_frame>
    <description>the patients will be monitored for safety (occurence of adverse events, vital signs, blood test parameters) following injection of the radiotracer 68Ga-NOTA-AE105</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantitative uptake of the radiotracer in tumor tissue</measure>
    <time_frame>2 hours</time_frame>
    <description>The patients will be PET scanned 10 minutes, 1 hour and 2 hours post injection of the radiotracer 68Ga-NOTA-AE105. These timepoints will be used for assessment of tumor uptake</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Urinary Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-NOTA-AE105 PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of 68Ga-NOTA-AE105 (app. 200 MBq) followed by 3 PET/CT scans 10 minutes, 1 hour and 2 hours post injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of 68Ga-NOTA-AE105</intervention_name>
    <description>One injection of 68Ga-NOTA-AE 105</description>
    <arm_group_label>68Ga-NOTA-AE105 PET</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Positron Emission Tomography scans</intervention_name>
    <description>Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection</description>
    <arm_group_label>68Ga-NOTA-AE105 PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. diagnosed with cancer of prostate, breast or urinary bladder

          2. capable of understanding and giving full informed consent

        Exclusion Criteria:

          1. pregnancy

          2. lactation

          3. contraindication for the use of intravenous CT contrast-agencies

          4. claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorthe Skovgaard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Persson M, Madsen J, Østergaard S, Jensen MM, Jørgensen JT, Juhl K, Lehmann C, Ploug M, Kjaer A. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med. 2012 Jan;53(1):138-45. doi: 10.2967/jnumed.110.083386.</citation>
    <PMID>22213823</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>August 21, 2015</last_update_submitted>
  <last_update_submitted_qc>August 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Dorthe Skovgaard</investigator_full_name>
    <investigator_title>MD, Phd</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

